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SUMMARY
Anti-cardiolipin antibodies, oxidatively modified low-density lipoproteins (oxLDL) and circulating
immune complexes are humoral factors that have been linked to vascular damage. To analyse their
possible role in the vascular complications in type 1 diabetes mellitus, we investigated patients with and
without vascular complications (retinopathy, nephropathy, polyneuropathy, foot ulcers). The patients
were matched for age, sex and duration of diabetes. The patients were also compared with 102 healthy
individuals. Anti-cardiolipin antibodies of IgG and IgA type were more common in patients compared
with healthy individuals. There was no difference between patients with and without vascular
complications. There was no increased prevalence of IgM anti-cardiolipin antibodies, but the levels
of these antibodies were higher in patients with vascular complications compared with patients without
complications and controls. Eighty-three percent of patients had circulating immune complexes in
comparison with 5% of healthy individuals. Such complexes were more common in patients with
complications. Both the prevalence and the levels of immune complexes were higher in patients with
null alleles of complement factor C4. Patients with vascular complications had higher prevalence of
C4A than of C4B null alleles. Anti-cardiolipin antibodies were present in higher relative concentrations
in immune complex form than in serum in all six patients analysed. There was no increased prevalence
of antibodies against oxidatively modified LDL in the patients. The higher prevalence and levels of anti-
cardiolipin antibodies and circulating immune complexes in patients with vascular complications
suggests that these humoral factors might be involved in the vascular complications of type 1 diabetes
mellitus.
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INTRODUCTION
Diabetes has been shown to be an independent risk factor for the
development of atherosclerosis and its complications. The patho-
physiological process is incompletely understood. Humoral factors
associated with accelerated atherosclerosis are anti-cardiolipin
antibodies (aCL), other negatively charged phospholipids, antibo-
dies against oxidatively modified low-density lipoproteins
(oxLDL) and circulating immune complexes (CIC). aCL have
been found in association with systemic lupus erythematosus
(SLE) [1], thrombovascular disease [2], thrombocytopenic purpura
[3] and myocardial infarction (MI) [4]. Patients with type 2
diabetes (NIDDM) have a higher prevalence of antiphospholipid
(aCL and/or phosphatidylserine) antibodies and the highest pre-
valence is observed in patients with macrovascular complications
[5]. The role of aCL in type 1 diabetes mellitus has not been
studied.
Antibodies against oxidatively modified LDL (oxLDL) have
been associated with the development of atherosclerosis [6], MI [7]
and peripheral vascular disease [8]. In NIDDM there was no
association between these antibodies and development of athero-
sclerosis [9], but their role in type 1 diabetes has not been
investigated.
CIC cause inflammation of the vessel wall and accelerate
atherosclerosis both in experimental animal models and in
humans [10]. Complement factor 4 (C4) plays a central role in
the solubilization and clearance of CIC [11]. C4 is encoded at two
highly polymorphic loci, C4A and C4B. One of the two C4A or
C4B genes may be null (deficient or non-expressed), termed as
C4A*Q0 or C4B*Q0. Null alleles are associated with immune
complex diseases such as SLE and have been implicated in
immune complex disease associated with premature MI [12].
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Patients with anti-phospholipid syndrome (APLS) have a high
prevalence of CIC containing these antibodies [13].
The purpose of this study was to investigate the possible
contribution of the humoral factors aCL, anti-oxLDL antibodies
and CIC to the vascular complications in type 1 diabetes mellitus.
PATIENTS AND METHODS
Patients
Sera of 38 patients, 20 male and 18 female, with type 1 diabetes
mellitus (c-peptide negative, early onset, ketosis-prone, insulin
therapy required at diagnosis) (mean age 46·8 years, range 29–
80 years) treated at the Department of Endocrinology and Diabe-
tology at the Karolinska Hospital, were studied. The patients had
been selected from a group of patients who were observed for
7 years. Half of the patients had developed vascular complications
at time of study. The groups were matched with regard to age, sex
and duration of disease. Criteria for exclusion were co-existent
autoimmune disorders, recent infective diseases and age
> 80 years. Vascular complications were defined by microangio-
pathy (presence of retinopathy assessed by routine ophthalmolo-
gical examination performed by an ophthalmologist,
microaneurysms with exudate and/or bleeding), nephropathy
defined as stable microalbuminuria of > 35 mg/24 h), peripheral
polyneuropathy assessed by sensation test, tendon reflexes and
vibration test with tuning fork. Six patients had foot ulcers. Nine-
teen patients without vascular complications had a mean diabetes
duration of 18 years, and 19 patients with vascular complications
had a mean diabetes duration of 20 years. Blood was collected in
the morning after overnight fasting. All patients had given their
informed consent to the study.
CIC and C4 allotypes were determined in the 38 patients and in
an additional 14 type 1 diabetic patients with vascular complica-
tions defined as above. The study was approved by the local ethics
committee.
Control population
The control group was composed of 102 age- and sex-matched
healthy individuals. Among them, 69 controls were randomly
selected from a population-based register from the Stockholm
County and 33 controls were randomly selected from healthy
blood donors. Of the 102 healthy controls, 56 were males and 46
were females (mean age 47·8 years, range 16–72 years). Indivi-
duals with autoimmune diseases were excluded.
Routine laboratory evaluations
The haematological investigations, acute-phase parameters and
serum biochemistry were done at the Department of Clinical
Chemistry, Karolinska Hospital. The analysis of complement
factors C3, C4 and C3d and immunoglobulins was carried out in
the Department of Clinical Immunology, Karolinska Hospital.
Autoantibodies
Rheumatoid factor, autoantibodies against nuclear antigens, gran-
ulocytes, proteinase 3, myeloperoxidase, smooth muscle and
mitochondria were analysed in the Department of Clinical Immu-
nology, Karolinska Hospital.
Determination of aCL
aCL were measured by ELISA, as described [14,15]. Both sera and
immunoglobulins from isolated immune complexes were tested
using this method.
Determination of antibodies against oxLDL
This was performed by ELISA as described [16].
Quantitative determination of CIC
This was performed by density gradient centrifugation and gel
filtration as described [13].
Isolation of CIC by precipitation
This was performed as described [17].
Determination of C4 allotypes
This was performed as described [18].
Statistical evaluation
The Mann–Whitney U-test was used for comparing data. Z
statistics were used for comparison between proportions of two
groups.
RESULTS
General investigations
Patients with signs of vascular complications had higher urinary
albumin excretion (P< 0·05), higher ASAT (P < 0·005), lower C4
(P< 0·05) and higher IgE (P < 0·05) values than patients without
such complications.
Anti-cardiolipin antibodies
The levels of aCL in all patients, with and without vascular
complications, and controls are reported in Fig. 1. The levels of
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Fig. 1. Box plot showing the levels of anti-cardiolipin antibodies in patients
without vascular complications (P1), patients with vascular complications
(P2) and healthy controls (C). The levels are expressed as optical density
(OD) values. The lower, mid and upper horizontal lines of the boxes
represent 25th, 50th, and 75th percentiles, respectively; the vertical lines
extend from the 10th to the 90th percentile. *Statistically different from
controls (P < 0·001); †statistically different from patients without compli-
cations (P1) and controls (C) (P< 0·005).
IgG and IgA aCL were higher in both patient groups than in the
control group (P < 0·001). There was no difference in patients with
and without complications. The levels of IgM aCL were higher in
patients with vascular complications than in patients without
complications or controls (P< 0·005).
The prevalence of IgG aCL was 21% (8/38) in all patients
and 4·9% (5/102) in controls (P < 0·005). The prevalence in
patients with complications was 31·5% (6/19) (P< 0·001
compared with controls) and in patients without complications
was 10·5% (2/19) (P > 0·05 compared with controls). There was
no significant difference between patients with and without
complications.
The prevalence of IgA aCL was 44·7% (17/38) in all patients
and 6·8% (7/102) in controls (P < 0·0001). The prevalence in
patients with complications was 47·3% (9/19) and in patients
without complications was 42·1% (8/19) (P > 0·0001 compared
with controls). There was no difference between patients with and
without complications.
The prevalence of IgM aCL did not differ between patients and
controls.
Antibodies against oxLDL
There was no increased prevalence or levels of antibodies against
oxLDL in both patient groups with and without vascular complica-
tions when compared with controls.
Circulating immune complexes and C4A*Q0
The concentrations of CIC are shown in Fig. 2. Eighty-three
percent of patients had CIC in comparison with 5% of the controls.
The prevalence in patients with complications was 90·9% and in
those without complications was 68·4% (P< 0·05). Patients with
complications also had higher concentrations of CIC than those
without complications (median concentration 67 mg/l versus
38 mg/l, P < 0·05).
Of patients with vascular complications, 16/33 had C4A*Q0
compared with 10/19 patients without complications. Patients with
complications more often had C4A*Q0 than C4B*Q0 (16/33
versus 5/33, P < 0·01). The prevalence of CIC in patients with
C4A*Q0 was higher than in patients with no C4A*Q0 (96·1%
versus 69·2%, P < 0·05), and there was also a difference in the
concentrations of CIC (median concentration 81·5 mg/l versus
37 mg/l, P< 0·005) (Fig. 2).
All the six patients tested had higher reactivity against cardi-
olipin in CIC than in serum. This difference was most pronounced
for IgA aCL (Table 1). The binding curves of non-complexed
antibodies in serum and antibodies derived from CIC are shown in
Fig. 3a–c. The slope of the binding curve was steeper and the
maximal binding was obtained using lower concentrations of
antibodies in the case of CIC-derived aCL compared with serum
aCL. This could indicate that aCL derived from CIC might be
concentrated in immune complex form or they might have a higher
affinity than those derived from serum.
DISCUSSION
The humoral factors analysed in this study have all been reported to
be associated with vasculitis and also with atherosclerosis and its
complications [4,7,8,10,12,15]. In this study, we have tried to
analyse their association with microangiopathy/atherosclerotic
complications in type 1 diabetes. There are few reports on aCL
in association with diabetes mellitus. In one study, the overall
frequency of anti-phospholipid antibodies in NIDDM was 51% and
the highest prevalence was observed in patients with macrovas-
cular complications (86%). The predominant isotypes of the
antibodies were IgG and IgA [5]. In another report, low titres of
aCL were observed in a mixed patient with type 1 and NIDDM
[19]. Our results show aCL of both IgG and IgA type with
increased prevalence in patients and with no difference in patients
with and without vascular complications. Regarding aCL of IgM
type, there was a higher level in patients with vascular complica-
tions only.
What initiates the formation of aCL is unknown. The higher
levels of IgM might indicate an ongoing and thus a more active
immune/inflammatory reaction against cardiolipin in patients with
vascular complications. IgA antibodies are usually initiated at the
mucosal level and IgA aCL are common after certain gastrointest-
inal and respiratory infections, possibly because of the frequent
occurrence of cardiolipin on certain microorganisms [20]. The
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Fig. 2. Box plot showing the levels of circulating immune complexes in
patients with no vascular complications, patients with vascular complica-
tions, patients with C4A*Q0 and patients with no C4A*Q0. The lower, mid
and upper horizontal lines of the boxes represent 25th, 50th, and 75th
percentiles, respectively; the vertical lines extend from the 10th to the 90th
percentile. *Statistically different from patients with no complications
(P< 0·05); †statistically different from patients with no C4A*Q0
(P< 0·005).
Table 1. Relative comparisons of circulating immune complex (CIC)–anti-
cardiolipin antibody (aCL) concentrations with serum–aCL concentrations.
The comparisons were made using the amounts of immunoglobulins that
gave the same absorbance value in the ELISA determination of aCL. The
reactivity for the serum–aCL was set to 1·0 [13]
Patient IgG IgM IgA
1 2 8 42
2 4 8 79
3 8 12 61
4 2 25 130
5 7 5 61
6 5 3 163
inducing event for these serum antibodies in diabetes might be an
infection on the mucosal surface.
The mechanism of action of aCL is also poorly understood.
These antibodies can bind to the phospholipids of endothelial cells
[21] and to the phospholipid epitopes on platelet membranes [3],
causing platelet activation and aggregation. A plasma cofactor
named b2-glycoprotein I (b2-GPI) is required for most antibody–
phospholipid interactions [22] and b2-GPI-dependent aCL induce
hypercoagulation or thrombus by blocking the inhibitory effect of
b2-GPI on the activation of factor X [23].
CIC are clearly related to both acute and chronic vascular
damage and elevated levels are present in both NIDDM and in type
1 diabetes mellitus [24,25]. An increased prevalence of IgA and/or
IgG immune complexes was found in patients, more frequently in
patients with microvascular complications [26,27]. In our study,
using a quantitative method for the estimation of CIC, we found an
increased prevalence in all patients and an even higher one in
patients with vascular complications. CIC may induce platelet
activation and aggregation and also activate the complement
system via the classical pathway [28–30]. Our patients with
vascular complications had lower C4 levels, suggesting such an
activation of the complement cascade. The higher IgE levels in
these patients is another, although non-specific, indication of
inflammatory vascular damage, since higher IgE levels are
common in patients with certain vasculitis.
The complement C4 is of major importance for the clearance of
immune complex from circulation, and C4A is four times more
efficient than C4B [31]. The relation between C4A*Q0 and
prevalence and concentration of CIC in our study reflects the
importance of C4A for CIC clearance. Moreover, the higher
prevalence of C4A*Q0 in patients with vascular complications
further supports the critical role of C4A and suggests that patients
with C4A*Q0 are specially predisposed to immune complex-
induced vascular complications.
Of interest was the relative concentration of aCL in CIC.
Such a concentration was also present in our earlier study [13]
and this presence of anti-cardiolipin reactivity in complexes might
endow them with special pathogenic potential, for example with
regard to binding to membrane phospholipids in addition to the Fc
binding.
There are conflicting reports on the association of autoanti-
bodies against oxLDL with atherosclerotic vascular disease in
NIDDM [9,32], and no such studies have been reported in type 1
diabetes. In the present study, there was no increased prevalence or
levels of anti-oxLDL antibodies in patients.
In conclusion, the higher prevalence and levels of aCL and CIC
in type 1 diabetes mellitus patients with vascular complications
point towards a possible role of these humoral factors in the
pathogenesis and/or progression of vascular complications in this
disease.
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